Generic Medicine Info
Indications and Dosage
Prophylaxis of postoperative anaerobic bacterial infections
Adult: 1 g by IV about 30 minutes before surgery.

Anaerobic bacterial infections
Adult: Initially, 0.5-1 g followed by 1 g daily as a single dose or in 2 divided doses for 5-10 days. Doses to be given via infusion. Substitute with 500 mg every 12 hr orally as soon as possible.
Child: 10 mg/kg every 12 hr for 5-10 days.

Severe amoebic dysentery, Amoebic liver abscess
Adult: Initially, 0.5-1 g infusion followed by 0.5 g every 12 hrs for 3-6 days.
Child: 20-30 mg/kg body wt daily.

Amoebic dysentery
Adult: 1.5 g as a single daily dose for 3 days. Alternatively for patients >60 kg: 1 g bid for 3 days.
Child: 40 mg/kg daily.

Adult: 1.5 g as a single daily dose or 0.5 g bid for 5 days. Treat sexual partners concomitantly.
Child: 25 mg/kg as a single dose.

Adult: 0.5 g bid for 5-10 days.
Child: 25 mg/kg as a single daily dose for 5-10 days.

Adult: 1-1.5 g as a single daily dose for 1-2 days.
Child: 30-40 mg/kg daily.
Renal Impairment
Haemodialysis patients: Give a supplemental dose (50% of the usual dose) before dialysis.
Hepatic Impairment
Severe: Double the interval between doses.
Should be taken with food.
Dilute to a concentration of ≤5 mg/ml.
Hypersensitivity to ornidazole or to other nitroimidazole derivatives.
Special Precautions
Renal and hepatic impairment. CNS diseases e.g. epilepsy or multiple sclerosis. May impair ability to drive or operate machinery. Pregnancy and lactation.
Adverse Reactions
Somnolence, headache, nausea, vomiting, dizziness, tremor, rigidity, poor coordination, seizures, tiredness, vertigo, temporary loss of consciousness and signs of sensory or mixed peripheral neuropathy, taste disturbances, abnormal LFTs, skin reactions.
Drug Interactions
Potentiates effect of coumarin-type oral anticoagulants. Prolongs the muscle-relaxant effect of vecuronium bromide.
Description: Ornidazole is a 5-nitroimidazole derivative active against protozoa and anaerobic bacteria. It is converted to reduction products that interact with DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms.
Absorption: Readily absorbed (oral and intravaginal); peak plasma concentrations after 2 hr (oral), 12 hr (intravaginal).
Distribution: Body tissues and fluids (wide), CSF. Protein-binding: <15%.
Metabolism: Hepatic.
Excretion: Via urine (as conjugates and metabolites), via faeces (small amounts); 12-14 hr (elimination half-life).
MIMS Class
Antiamoebics / Other Antibiotics
Disclaimer: This information is independently developed by MIMS based on Ornidazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in